WO2000005397A1 - Improved process for clavulanic acid production - Google Patents

Improved process for clavulanic acid production Download PDF

Info

Publication number
WO2000005397A1
WO2000005397A1 PCT/PT1999/000012 PT9900012W WO0005397A1 WO 2000005397 A1 WO2000005397 A1 WO 2000005397A1 PT 9900012 W PT9900012 W PT 9900012W WO 0005397 A1 WO0005397 A1 WO 0005397A1
Authority
WO
WIPO (PCT)
Prior art keywords
fermentation
concentration
broth
culture
clavulanic acid
Prior art date
Application number
PCT/PT1999/000012
Other languages
French (fr)
Inventor
Ana Maria De Almeida Nabais
Maria Manuela Regalo Da Fonseca
Original Assignee
Dsm N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm N.V. filed Critical Dsm N.V.
Priority to MXPA01000653A priority Critical patent/MXPA01000653A/en
Priority to AU48088/99A priority patent/AU4808899A/en
Priority to CA002337074A priority patent/CA2337074A1/en
Priority to EP99931644A priority patent/EP1098989A1/en
Publication of WO2000005397A1 publication Critical patent/WO2000005397A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Definitions

  • This invention is related to important improvements in the clavulanic acid fermentation using strains of Streptomyces clavuligerus, low cost complex media and strategies of easy industrial implementation.
  • Clavulanic acid is used in medicine in association with antibiotics that are inactivated by ⁇ - lactamases.
  • Clavulanic acid (3-(2-hydroxyethylidene)-7-oxo-4-oxa-l-azabi- cyclo[3.2.0]heptane-2-carboxylic acid) is a molecule that has the structural formula
  • This acid has weak antibacterial activity. However, it is a potent inhibitor of ⁇ -lactamase enzymes produced by many strains of Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus, Shigella, Pseudomonas and Haemophilus influenzae.
  • ⁇ -Lactamases through the hydrolysis of the ⁇ -lactam ring, inactivate several antibiotics, and make the microorganisms, which produce them, resistant to those antibiotics.
  • clavulanic acid As potent inhibitor of ⁇ -lactamases, clavulanic acid is able to avoid this mechanism of resistance, widening the antibacterial activity spectrum of several antibiotics. Clavulanic acid presents good synergetic activity when associated with antibiotics such as amoxycillin, ampicillin, carbenicillin, ticarcillin, benzylpenicillin or cephaloridine, against ⁇ -lactamase-producing organisms.
  • clavulanic acid production by Streptomyces clavuligerus for example (a) discontinuous fermentation using complex or chemically defined media (BR Patent 1 508 977, Beecham Group Ltd.); (b) fermentation with automatic control of pH between 6.3 and 6.7 (BR Patent 1 571 888, Glaxo Laboratories Ltd.); (c) fermentation with continuous or semicontinuous feeding of a carbon source (for example maltose or glycerol) (ES Patent 537 157, Antibioticos, S.A.); and (d) fermentation with control of soluble phosphate in the medium, at the beginning and throughout the fermentation (EP Patent 0 811 689, Antibioticos, S.A.).
  • a carbon source for example maltose or glycerol
  • the present invention concerns a process for clavulanic acid production by a technique of fermentation which includes the aerobic submerged culture using selected and/or culture collection strains of Streptomyces clavuligerus, or mutants thereof. Accordingly, the culture is carried out with continuous or semicontinuous feeding of one or more organic nitrogen complex sources, preferably soybean meal, so as to control the protein concentration in the filtered broth within certain limits during the time course of the fermentation.
  • one or more organic nitrogen complex sources preferably soybean meal
  • this invention describes new process strategies for clavulanic acid production by cultivating the producing microorganism, as for example Streptomyces clavuligerus ATCC 27064, or mutants thereof, in aerobic submerged culture using low cost complex media, in distinct conditions from those patented or reported to date, leading to important improvements in clavulanic acid fermentation.
  • These conditions consist in the continuous or staggered feeding of one or more organic nitrogen complex sources, in order to control the protein concentration in the filtered broth within certain limits during the fermentation, since very high values may inhibit/repress the biosynthesis of the antibiotic, and very low values may be limiting for the desired biosynthesis.
  • the organic nitrogen complex sources can be seed protein such as soybean meal, peanut meal, cottonseed meal and linseed meal, fish meal, hydrolysates and filtrates of such proteins, meat extracts and hydrolysates such as peptones, being, preferably, soybean meal.
  • the amount of organic nitrogen complex source to be fed in a continuous or semicontinuous mode can be in the daily concentration of 0.1-1.5%, preferably between 0.18 and 1.0%, and/or may be such that the protein concentration in the filtered broth is between 200 and 3500 mg/L, preferably 400- 1500 mg/L throughout the fermentation.
  • the initial culture medium can be composed by one or more organic nitrogen complex sources and, additionally, one or more carbon sources.
  • concentration of the organic nitrogen complex source may fall preferably between 1.3 and 1.8%.
  • the carbon sources may be glycerol and/or carbohydrates like starch, starch hydrolysates, dextrins and maltose. It was observed that the simultaneous use of glycerol and dextrin in the initial culture medium, preferably in the concentration ranges of, respectively, 0.9-1.3% and 1.8-2.2%, improve the production of clavulanic acid.
  • one or more carbon sources may be fed continuously or semicontinuously in daily concentrations between 0.18% and 1%, and/or so that the glycerol concentration in the filtered broth is between 0.2 and 12 g/L, and/or the dextrin or maltose concentrations in the filtered broth are in the range 4-22 g/L or 2-12 g/L, respectively, during the time course of the fermentation. It was observed that the simultaneous feeding of glycerol and dextrin or maltose improve the production of clavulanic acid.
  • the fermentation can be performed with continuous or semicontinuous partial discharges of fermentation broth on such way as to maintain the volume of fermentation broth between 35 and 65% of the total fermenter capacity.
  • the agitator speed can be progressively increased, according to the increase in volume, broth viscosity and dry weight concentration during the fermentation, so as to improve the mixing and the dissolved oxygen levels in the culture.
  • the culture can be carried out at a temperature between 26 and 29°C and the pH can be controlled between 6.5 and 6.8 by automatic addition of acid and base, such as a hydrochloric acid solution and a sodium hydroxide solution.
  • acid and base such as a hydrochloric acid solution and a sodium hydroxide solution.
  • Foam can be controlled by addition of antifoam, as for example, a silicone suspension.
  • the fermentation vessel should be a typical tank for aerobic fermentation with agitation and aeration devices.
  • the aeration volumetric flow rate per unit of broth volume may be 0.6 to 1.3 vvm.
  • These tanks should be supplied with aseptic systems for continuous or semicontinuous feeding of several nutrients in the form of solution and/or suspension, with aseptic systems for continuous or semicontinuous partial discharges of fermentation broth, and possibly with variable agitator speed.
  • the samples of culture broth may be vacuum filtered, preferably through filter paper previously dried in an oven at 86°C for 12 h. After the filtered broth has been collected, the filter paper with the mycelium is washed with distilled water and subsequently dried in an oven at 86°C for 24 h. The dry weight concentration of the sample is thus obtained.
  • the clavulanic acid, protein, glycerol, dextrin or maltose concentrations can be measured in the filtered broth by spectrophotometric methods or, preferably, by high pressure liquid chromatographic methods, for example using the methods described in (Bird, A.E. et al. 1982, Analyst 107: 1241-1245; Foulstone, M. and Reading, C. 1982, Antimicrob. Agents Chemother. 22: 753-762), (Bradford, M.M. 1976, Anal. Biochem. 72: 248-254), (Bok, S.H. and Demain, A.L. 1977, Anal. Biochem. 81 : 18-20), (Nelson, N. 1944, J. Biol. Chem. 153: 375-380; Somogyi, M. 1952, J. Biol. Chem. 195: 19-23) respectively.
  • a spore suspension of Streptomyces clavuligerus ATCC 27064 was prepared from agar slants containing hydrated dextrin 10 g, yeast extract 1 g, meat extract 1 g, bacteriological peptone 2 g, CaC0 3 2 g, agar 20 g, per litre of distilled water. The pH was corrected to 7.1 with 1M NaOH and 1M HC1.
  • This spore suspension was used to inoculate various 500 mL conical flasks containing 50 mL of culture medium A (soybean meal 15 g, (87%) glycerol 10 g, hydrated dextrin 10 g, KH 2 PO 1 g, per litre of distilled water).
  • culture medium A serum meal 15 g, (87%) glycerol 10 g, hydrated dextrin 10 g, KH 2 PO 1 g, per litre of distilled water.
  • the pH was corrected to 7.2 with 1M NaOH and 1M HC1.
  • the flasks were sterilized at 121°C for 15 min and incubated at 30°C and 110-140 rpm during 2 days. The content of 5 flasks was then mixed, giving the vegetative inoculum.
  • a culture medium B composed by soybean meal 15 g, (87%) glycerol 13 g, hydrated dextrin 20 g, (50%) silicone suspension 1 g, per litre of tap water, was introduced into a 8 litre STR fermenter and sterilized for 20 min at about 120°C.
  • the fermenter was inoculated with the vegetative inoculum prepared previously.
  • the fermentation was carried out with automatic control of pH at 6.6 ⁇ 0,05 by addition of a 5% (v/v) HCl solution and IM NaOH solution. Foam was controlled by addition of a 50% silicone suspension. The temperature was kept between 26 and 29°C, and the aeration between 0.7 and 1.2 wm.
  • the volumetric flow rate was controlled manually according to the result of the daily analysis of protein and glycerol concentrations in the filtered culture broth.
  • the volumetric flow rate varied throughout the time course of the fermentation as follows:
  • the volumetric flow rate was manually controlled according to the result of the daily analysis of protein, glycerol, and dextrin concentrations in the filtered broth.
  • the volumetric flow rate varied in the following way throughout the time course of the fermentation :
  • Partial discharges of fermentation broth were carried out (8.3% v/v) at 100 and 123 h, using a peristaltic pump with manual control, according to the increase in volume of culture broth in the fermenter.
  • volume of fermentation broth volume of partial discharges of fermentation broth, dry weight concentration, clavulanic acid titre and protein, glycerol and dextrin concentrations in the filtered broth along the fermentation process were obtained:
  • the culture broth At 143 h the culture broth attained a volume of 4.15 L, a clavulanic acid titre of 1374 ⁇ g/mL and a dry weight concentration of 18.7 g/L. In other words, 1839 ⁇ g of clavulanic acid and 25.0 mg of dry weight per mL of culture medium B were obtained. Considering the partial discharges, a total of 2099 ⁇ g of clavulanic acid and 28.8 mg of dry weight per mL of culture medium B were obtained.
  • Culture medium B was replaced by culture medium E composed by soybean meal 15 g and (50%) silicone suspension 2 g, per litre of tap water.
  • the volumetric flow rate was manually controlled according to the result of the daily analysis of the protein, glycerol and maltose concentrations in the filtered broth.
  • the volumetric flow rate varied throughout the fermentation time as follows: TABLE VII
  • the agitator speed and the dissolved oxygen concentration varied during the fermentation as follows:
  • Partial discharges of fermentation broth were performed through a peristaltic pump of manual control, according to the increase in volume of culture broth in the fermenter.
  • partial discharges of fermentation broth of 8.3%, 7.2%, 10.3%. 10.5% and 7.3% (v/v) at 96, 120, 144, 168 and 192 h, respectively, were carried out.
  • volume of fermentation broth volume of partial discharges of fermentation broth, dry weight concentration, clavulanic acid titre and protein, glycerol and maltose concentrations in the filtered broth throughout the time course of the fermentation were obtained:
  • the culture broth attained a volume of 4.02 L, a clavulanic acid titre of 1607 ⁇ g/mL and a dry weight concentration of 16.6 g/L.
  • 2084 ⁇ g of clavulanic acid and 21.5 mg of dry weight per mL of culture medium E were obtained.
  • a total of 2790 ⁇ g of clavulanic acid and 30.6 mg of dry weight per mL of culture medium E were attained.

Abstract

The present invention concerns a process for clavulanic acid production by aerobic fermentation using selected and/or culture collection strains of Streptomyces clavuligerus, or mutants thereof. Accordingly, the culture is carried out with continuous or semicontinuous feeding of one or more organic nitrogen complex sources, preferably soybean meal, so as to control the protein concentration in the filtered broth within certain limits during the time course of the fermentation. The described conditions led to significant improvements in the clavulanic acid fermentation.

Description

DESCRIPTION
"IMPROVED PROCESS FOR CLAVULANIC ACID PRODUCTION"
Scope of the Invention
This invention is related to important improvements in the clavulanic acid fermentation using strains of Streptomyces clavuligerus, low cost complex media and strategies of easy industrial implementation. Clavulanic acid is used in medicine in association with antibiotics that are inactivated by β- lactamases.
Background to the Invention
Clavulanic acid (3-(2-hydroxyethylidene)-7-oxo-4-oxa-l-azabi- cyclo[3.2.0]heptane-2-carboxylic acid) is a molecule that has the structural formula
Figure imgf000003_0001
H
This acid has weak antibacterial activity. However, it is a potent inhibitor of β-lactamase enzymes produced by many strains of Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus, Shigella, Pseudomonas and Haemophilus influenzae. β-Lactamases, through the hydrolysis of the β-lactam ring, inactivate several antibiotics, and make the microorganisms, which produce them, resistant to those antibiotics.
As potent inhibitor of β-lactamases, clavulanic acid is able to avoid this mechanism of resistance, widening the antibacterial activity spectrum of several antibiotics. Clavulanic acid presents good synergetic activity when associated with antibiotics such as amoxycillin, ampicillin, carbenicillin, ticarcillin, benzylpenicillin or cephaloridine, against β-lactamase-producing organisms.
There are several microorganisms which produce clavulanic acid, namely Streptomyces clavuligerus, Streptomyces jumonjinensis (ES Patent 543 854) and Streptomyces katsurahamanus (JP Patent 53-104796, Takeda Chemical Industries, Ltd.). There are various processes described for clavulanic acid production by Streptomyces clavuligerus, for example (a) discontinuous fermentation using complex or chemically defined media (BR Patent 1 508 977, Beecham Group Ltd.); (b) fermentation with automatic control of pH between 6.3 and 6.7 (BR Patent 1 571 888, Glaxo Laboratories Ltd.); (c) fermentation with continuous or semicontinuous feeding of a carbon source (for example maltose or glycerol) (ES Patent 537 157, Antibioticos, S.A.); and (d) fermentation with control of soluble phosphate in the medium, at the beginning and throughout the fermentation (EP Patent 0 811 689, Antibioticos, S.A.).
In discontinuous fermentations of Streptomyces clavuligerus using soluble media, it is generally observed that the time course of clavulanic acid titre is closely related to the dry weight concentration until a maximum value is reached, followed by a decay of both. Decay of dry weight concentration is ascribed to sporulation and/or mycelium lysis. Decay of clavulanic acid titre can be due to its degradation rate being higher than its production rate. Description of the Invention
The present invention concerns a process for clavulanic acid production by a technique of fermentation which includes the aerobic submerged culture using selected and/or culture collection strains of Streptomyces clavuligerus, or mutants thereof. Accordingly, the culture is carried out with continuous or semicontinuous feeding of one or more organic nitrogen complex sources, preferably soybean meal, so as to control the protein concentration in the filtered broth within certain limits during the time course of the fermentation.
The conditions described in this invention successfully led to the following important improvements in clavulanic acid fermentation: (a) a significant increase in the clavulanic acid production; (b) the prevention of mycelium lysis throughout the fermentation; (c) a continuous increase in the clavulanic acid titre and in the dry weight concentration throughout the fermentation (without partial discharges of fermentation broth); and/or (d) a continuous increase in the clavulanic acid titre, maintaining the dry weight concentration approximately constant from a certain point in time (with partial discharges of fermentation broth).
Therefore, this invention describes new process strategies for clavulanic acid production by cultivating the producing microorganism, as for example Streptomyces clavuligerus ATCC 27064, or mutants thereof, in aerobic submerged culture using low cost complex media, in distinct conditions from those patented or reported to date, leading to important improvements in clavulanic acid fermentation. These conditions consist in the continuous or staggered feeding of one or more organic nitrogen complex sources, in order to control the protein concentration in the filtered broth within certain limits during the fermentation, since very high values may inhibit/repress the biosynthesis of the antibiotic, and very low values may be limiting for the desired biosynthesis. The organic nitrogen complex sources can be seed protein such as soybean meal, peanut meal, cottonseed meal and linseed meal, fish meal, hydrolysates and filtrates of such proteins, meat extracts and hydrolysates such as peptones, being, preferably, soybean meal. The amount of organic nitrogen complex source to be fed in a continuous or semicontinuous mode can be in the daily concentration of 0.1-1.5%, preferably between 0.18 and 1.0%, and/or may be such that the protein concentration in the filtered broth is between 200 and 3500 mg/L, preferably 400- 1500 mg/L throughout the fermentation.
According to this process, the initial culture medium can be composed by one or more organic nitrogen complex sources and, additionally, one or more carbon sources. The concentration of the organic nitrogen complex source may fall preferably between 1.3 and 1.8%. The carbon sources may be glycerol and/or carbohydrates like starch, starch hydrolysates, dextrins and maltose. It was observed that the simultaneous use of glycerol and dextrin in the initial culture medium, preferably in the concentration ranges of, respectively, 0.9-1.3% and 1.8-2.2%, improve the production of clavulanic acid.
Additionally, one or more carbon sources may be fed continuously or semicontinuously in daily concentrations between 0.18% and 1%, and/or so that the glycerol concentration in the filtered broth is between 0.2 and 12 g/L, and/or the dextrin or maltose concentrations in the filtered broth are in the range 4-22 g/L or 2-12 g/L, respectively, during the time course of the fermentation. It was observed that the simultaneous feeding of glycerol and dextrin or maltose improve the production of clavulanic acid.
The fermentation can be performed with continuous or semicontinuous partial discharges of fermentation broth on such way as to maintain the volume of fermentation broth between 35 and 65% of the total fermenter capacity. The agitator speed can be progressively increased, according to the increase in volume, broth viscosity and dry weight concentration during the fermentation, so as to improve the mixing and the dissolved oxygen levels in the culture.
The culture can be carried out at a temperature between 26 and 29°C and the pH can be controlled between 6.5 and 6.8 by automatic addition of acid and base, such as a hydrochloric acid solution and a sodium hydroxide solution. Foam can be controlled by addition of antifoam, as for example, a silicone suspension.
The fermentation vessel should be a typical tank for aerobic fermentation with agitation and aeration devices. The aeration volumetric flow rate per unit of broth volume may be 0.6 to 1.3 vvm. These tanks should be supplied with aseptic systems for continuous or semicontinuous feeding of several nutrients in the form of solution and/or suspension, with aseptic systems for continuous or semicontinuous partial discharges of fermentation broth, and possibly with variable agitator speed.
To carry out the analysis, the samples of culture broth may be vacuum filtered, preferably through filter paper previously dried in an oven at 86°C for 12 h. After the filtered broth has been collected, the filter paper with the mycelium is washed with distilled water and subsequently dried in an oven at 86°C for 24 h. The dry weight concentration of the sample is thus obtained.
The clavulanic acid, protein, glycerol, dextrin or maltose concentrations can be measured in the filtered broth by spectrophotometric methods or, preferably, by high pressure liquid chromatographic methods, for example using the methods described in (Bird, A.E. et al. 1982, Analyst 107: 1241-1245; Foulstone, M. and Reading, C. 1982, Antimicrob. Agents Chemother. 22: 753-762), (Bradford, M.M. 1976, Anal. Biochem. 72: 248-254), (Bok, S.H. and Demain, A.L. 1977, Anal. Biochem. 81 : 18-20), (Nelson, N. 1944, J. Biol. Chem. 153: 375-380; Somogyi, M. 1952, J. Biol. Chem. 195: 19-23) respectively.
A summary of the results obtained is presented through the various examples that follow.
EXAMPLE 1
A spore suspension of Streptomyces clavuligerus ATCC 27064 was prepared from agar slants containing hydrated dextrin 10 g, yeast extract 1 g, meat extract 1 g, bacteriological peptone 2 g, CaC03 2 g, agar 20 g, per litre of distilled water. The pH was corrected to 7.1 with 1M NaOH and 1M HC1.
This spore suspension was used to inoculate various 500 mL conical flasks containing 50 mL of culture medium A (soybean meal 15 g, (87%) glycerol 10 g, hydrated dextrin 10 g, KH2PO 1 g, per litre of distilled water). The pH was corrected to 7.2 with 1M NaOH and 1M HC1. The flasks were sterilized at 121°C for 15 min and incubated at 30°C and 110-140 rpm during 2 days. The content of 5 flasks was then mixed, giving the vegetative inoculum.
Separately, 3.1 L of a culture medium B composed by soybean meal 15 g, (87%) glycerol 13 g, hydrated dextrin 20 g, (50%) silicone suspension 1 g, per litre of tap water, was introduced into a 8 litre STR fermenter and sterilized for 20 min at about 120°C. The fermenter was inoculated with the vegetative inoculum prepared previously.
The fermentation was carried out with automatic control of pH at 6.6±0,05 by addition of a 5% (v/v) HCl solution and IM NaOH solution. Foam was controlled by addition of a 50% silicone suspension. The temperature was kept between 26 and 29°C, and the aeration between 0.7 and 1.2 wm.
At 24 h the staggered feeding of a culture medium C composed by soybean meal 65 g and (87%) glycerol 100 g, per litre of tap water, was started, using a peristaltic pump of variable rate. The volumetric flow rate was controlled manually according to the result of the daily analysis of protein and glycerol concentrations in the filtered culture broth. Thus, the volumetric flow rate varied throughout the time course of the fermentation as follows:
Figure imgf000009_0001
Since the volume, broth viscosity and dry weight concentration increased throughout the course of the fermentation, the agitator speed was manually increased, on such way as to improve the mixing and the dissolved oxygen levels in the culture. Thus, the agitator speed and the dissolved oxygen concentration varied in the following way during the fermentation: TABLE II
Figure imgf000010_0001
The following values of volume of fermentation broth, dry weight concentration, clavulanic acid titre and protein, glycerol and dextrin concentrations in the filtered broth, throughout the time course of the fermentation, were obtained:
TABLE III
Figure imgf000010_0002
Sporulation was observed under the microscope throughout the fermentation, but mycelium lysis was not detected. At 166 h the culture broth attained a volume of 4.92 L, a clavulanic acid titre of 1224 μg/mL and a dry weight concentration of 15.6 g/L. In other words, 1943 μg of clavulanic acid and 24.8 mg of dry weight per mL of culture medium B were obtained.
EXAMPLE 2
The fermentation was carried out as described in example 1 , except for the changes described next.
The staggered feeding of a culture medium D composed by soybean meal 65 g, (87%) glycerol 56.3 g, hydrated dextrin 86.6 g and (50%) silicone suspension 2 g, per litre of tap water, was carried out from 24 h fermentation time until the end of the fermentation. The volumetric flow rate was manually controlled according to the result of the daily analysis of protein, glycerol, and dextrin concentrations in the filtered broth. Thus, the volumetric flow rate varied in the following way throughout the time course of the fermentation :
TABLE IV
Figure imgf000011_0001
The agitator speed and the dissolved oxygen concentration varied throughout the fermentation time as follows: TABLE V
Figure imgf000012_0001
Partial discharges of fermentation broth were carried out (8.3% v/v) at 100 and 123 h, using a peristaltic pump with manual control, according to the increase in volume of culture broth in the fermenter.
The following values of volume of fermentation broth, volume of partial discharges of fermentation broth, dry weight concentration, clavulanic acid titre and protein, glycerol and dextrin concentrations in the filtered broth along the fermentation process were obtained:
TABLE VI
Figure imgf000012_0002
Sporulation throughout the fermentation, and the beginning of mycelium lysis at the end of the fermentation (at 143 h) were observed under the microscope.
At 143 h the culture broth attained a volume of 4.15 L, a clavulanic acid titre of 1374 μg/mL and a dry weight concentration of 18.7 g/L. In other words, 1839 μg of clavulanic acid and 25.0 mg of dry weight per mL of culture medium B were obtained. Considering the partial discharges, a total of 2099 μg of clavulanic acid and 28.8 mg of dry weight per mL of culture medium B were obtained.
EXAMPLE 3
The fermentation was carried out according to example 1, except for the changes described next.
Culture medium B was replaced by culture medium E composed by soybean meal 15 g and (50%) silicone suspension 2 g, per litre of tap water.
The staggered feeding of a culture medium F composed by soybean meal 65 g, (87%) glycerol 70 g and monohydrated maltose 65 g, per litre of tap water, took place from 0 h of fermentation time. The volumetric flow rate was manually controlled according to the result of the daily analysis of the protein, glycerol and maltose concentrations in the filtered broth. Thus, the volumetric flow rate varied throughout the fermentation time as follows: TABLE VII
Figure imgf000014_0001
The agitator speed and the dissolved oxygen concentration varied during the fermentation as follows:
TABLE VIII
Figure imgf000014_0002
Partial discharges of fermentation broth were performed through a peristaltic pump of manual control, according to the increase in volume of culture broth in the fermenter. Thus, partial discharges of fermentation broth of 8.3%, 7.2%, 10.3%. 10.5% and 7.3% (v/v) at 96, 120, 144, 168 and 192 h, respectively, were carried out.
The following values of volume of fermentation broth, volume of partial discharges of fermentation broth, dry weight concentration, clavulanic acid titre and protein, glycerol and maltose concentrations in the filtered broth throughout the time course of the fermentation were obtained:
TABLE IX
Figure imgf000015_0001
Sporulation was observed under the microscope throughout the fermentation, but no mycelium lysis was detected.
At 216 h the culture broth attained a volume of 4.02 L, a clavulanic acid titre of 1607 μg/mL and a dry weight concentration of 16.6 g/L. In other words, 2084 μg of clavulanic acid and 21.5 mg of dry weight per mL of culture medium E were obtained. Taking into consideration the partial discharges, a total of 2790 μg of clavulanic acid and 30.6 mg of dry weight per mL of culture medium E were attained.

Claims

1. Process for clavulanic acid production by a technique of fermentation which includes the aerobic submerged culture using selected and/or culture collection strains of Streptomyces clavuligerus, or mutants thereof, wherein the culture is carried out with continuous or semicontinuous feeding of one or more organic nitrogen complex sources, preferably soybean meal, in order to control the protein concentration in the filtered broth within certain limits during the time course of the fermentation.
2. Process according to claim 1, wherein the organic nitrogen complex sources are seed protein such as soybean meal, peanut meal, cottonseed meal and linseed meal, fish meal, hydrolysates and filtrates of such proteins, meat extracts and hydrolysates such as peptones.
3. Process according to claim 1 or 2, wherein the amount of organic nitrogen complex source to be fed in a continuous or semicontinuous mode is in the daily concentration of 0.1-1.5%, preferably between 0.18 and 1.0%, and/or is such that the protein concentration in the filtered broth is between 200 and 3500 mg/L, preferably 400-1500 mg/L, during the fermentation.
4. Process according to any of the claims 1 to 3, wherein the initial culture medium is constituted preferably by one or more organic nitrogen complex sources in a concentration between 1.3 and 1.8%, glycerol and dextrin in the concentration range 0.9-1.3% and 1.8-2.2%, respectively.
5. Process according to any of the claims 1 to 4, wherein glycerol and dextrin or maltose are additionally fed, continuous or semicontinuously, at a daily concentration between 0.18 and 1%, and/or so that the glycerol concentration in the filtered broth is in the range 0.2-12 g/L, and so that the dextrin or maltose concentration in the filtered broth is 4-22 g/L or 2-12 g/L, respectively, throughout the fermentation.
6. Process according to any of the claims 1 to 5, wherein continuous or semicontinuous partial discharges of fermentation broth are performed on such way as to maintain the volume of fermentation broth between 35 and 65% of the total fermenter capacity.
7. Process according to any of the preceding claims, wherein the agitator speed is progressively increased according to the increase in volume, broth viscosity and dry weight concentration during the fermentation, on such way as to improve the mixing, as well as the dissolved oxygen levels in the culture.
PCT/PT1999/000012 1998-07-20 1999-07-19 Improved process for clavulanic acid production WO2000005397A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA01000653A MXPA01000653A (en) 1998-07-20 1999-07-19 Improved process for clavulanic acid production.
AU48088/99A AU4808899A (en) 1998-07-20 1999-07-19 Improved process for clavulanic acid production
CA002337074A CA2337074A1 (en) 1998-07-20 1999-07-19 Improved process for clavulanic acid production
EP99931644A EP1098989A1 (en) 1998-07-20 1999-07-19 Improved process for clavulanic acid production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT102181 1998-07-20
PT10218198A PT102181A (en) 1998-07-20 1998-07-20 IMPROVED PROCESS FOR THE PRODUCTION OF CLAVULANIC ACID

Publications (1)

Publication Number Publication Date
WO2000005397A1 true WO2000005397A1 (en) 2000-02-03

Family

ID=20085781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PT1999/000012 WO2000005397A1 (en) 1998-07-20 1999-07-19 Improved process for clavulanic acid production

Country Status (8)

Country Link
EP (1) EP1098989A1 (en)
CN (1) CN1310766A (en)
AU (1) AU4808899A (en)
CA (1) CA2337074A1 (en)
MX (1) MXPA01000653A (en)
PT (1) PT102181A (en)
TR (1) TR200100167T2 (en)
WO (1) WO2000005397A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102277310A (en) * 2010-06-11 2011-12-14 中国科学院上海生命科学研究院 Vector-host system for expressing antibiotic gene clusters and application thereof
EP2589663A1 (en) 2011-11-04 2013-05-08 LEK Pharmaceuticals d.d. Process for production of clavulanic acid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132531A1 (en) * 2007-04-27 2008-11-06 Council Of Scientific And Industrial Research Process for the preparation of clavulanic acid employing streptomyces clavuligerus mtcc 1142 in a solid state fermentation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604697A1 (en) * 1975-02-07 1976-08-19 Glaxo Lab Ltd ANTIBIOTICS
US4525353A (en) * 1974-04-20 1985-06-25 Beecham Group P.L.C. Antibiotics
EP0811689A1 (en) * 1995-11-23 1997-12-10 Antibioticos, S.A. Process for the production of clavulanic acid and/or salts thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525353A (en) * 1974-04-20 1985-06-25 Beecham Group P.L.C. Antibiotics
DE2604697A1 (en) * 1975-02-07 1976-08-19 Glaxo Lab Ltd ANTIBIOTICS
EP0811689A1 (en) * 1995-11-23 1997-12-10 Antibioticos, S.A. Process for the production of clavulanic acid and/or salts thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APPL. MICROBIOL. BIOTECHNOL. (1996), 45(1-2), 41-6 *
CHEMICAL ABSTRACTS, vol. 122, no. 17, 24 April 1995, Columbus, Ohio, US; abstract no. 206718, PARADKAR, ASHISH S. ET AL: "Functional analysis of the gene encoding the clavaminate synthase 2 isoenzyme involved in clavulanic acid biosynthesis in Streptomyces-- clavuligerus" XP002118367 *
CHEMICAL ABSTRACTS, vol. 124, no. 25, 17 June 1996, Columbus, Ohio, US; abstract no. 340966, MAYER, A. F. ET AL: "Simultaneous production and decomposition of clavulanic acid during Streptomyces clavuligerus cultivations" XP002118366 *
J. BACTERIOL. (1995), 177(5), 1307-14 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102277310A (en) * 2010-06-11 2011-12-14 中国科学院上海生命科学研究院 Vector-host system for expressing antibiotic gene clusters and application thereof
EP2589663A1 (en) 2011-11-04 2013-05-08 LEK Pharmaceuticals d.d. Process for production of clavulanic acid
WO2013064687A2 (en) 2011-11-04 2013-05-10 Lek Pharmaceuticals D.D. Process for production of clavulanic acid

Also Published As

Publication number Publication date
MXPA01000653A (en) 2002-04-08
PT102181A (en) 2000-01-31
TR200100167T2 (en) 2001-05-21
CN1310766A (en) 2001-08-29
CA2337074A1 (en) 2000-02-03
AU4808899A (en) 2000-02-14
EP1098989A1 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
WO2010058427A2 (en) Process for production and purification of polymyxin b sulfate
Jung et al. Optimization of culture conditions and scale-up to pilot and plant scales for vancomycin production by Amycolatopsis orientalis
Boeck et al. NEW AZASTEROIDAL ANTIFUNGAL ANTIBIOTICS FROM GEOTRICHU FLAVO-BRUNNEUM I. DISCOVERY AND FERMENTATION STUDIES
AU729094B2 (en) Process for producing clavulanic acid and/or its salts
WO2000005397A1 (en) Improved process for clavulanic acid production
GB2058776A (en) Esters and their use in the synthesis of -lactam antibacterial compounds
US4091092A (en) Polymyxin F and process of producing polymyxin F
WO1997039137A1 (en) Process for the preparation of clavulanic acid
KR100373510B1 (en) Teicoplanin producing microorganism
KR930000276B1 (en) Method for producing cephem compounds
RU2761482C1 (en) Streptomyces olivaceiscleroticus strain - producer of the antitumor antibiotic olivomycin
YAMASHITA et al. FR-900318, a novel penicillin with β-lactamase inhibitory activity
El-Enshasy et al. Improvement of rifemycins production by Amycolatopsis mediterranei in batch and fed-batch cultures
Tanaka Fermentation processes in screening for new bioactive substances
KR910004371B1 (en) Method for preparation of cephalosporin -c
KR20000002408A (en) Glutamic acid producible microorganism and preparation method of glutamic acid by using it
US4298599A (en) Novel antibiotic BN-235 substance, and process for the production thereof
US3922202A (en) Fermentation process
US3886044A (en) Process of making cephamycin C by fermentation
US3901972A (en) Antibiotic xk' 33' f' 2 'and process for producing same
Abou-Zeid et al. Utilisation of molasses as a natural medium for production of magnamycin by Streptomyces halsted II
KR960004037B1 (en) Micro-organism that produces cephalosporin c, and the processing method of cephalosporin c with using it
Okabe et al. Preferential production of a carbapenem antibiotic, PS-5 by dissolved oxygen controlled fermentation
JPS6250473B2 (en)
KR960004036B1 (en) Microorganism that produces cephalosporin c and the processing method of cephalosporin c with using it

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808891.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999931644

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2337074

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00046/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000653

Country of ref document: MX

Ref document number: 2001/00167

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999931644

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09743722

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999931644

Country of ref document: EP